Abstract
The aim of this study was to test the contribution of anti-myelin antibodies in predicting conversion from clinically isolated syndrome (CIS) to multiple sclerosis (MS) when considering either Poser's or McDonald's diagnostic criteria. Fifty-one patients with CIS and abnormal brain MRI were imaged monthly for six months and then at 12, 18, 24, 36 months. At baseline serum samples testing antibodies against myelin oligodendrocyte glycoprotein (anti-MOG) and myelin basic protein (anti-MBP) were collected. During the 36-month follow-up, 26 (51%) patients developed a relapse thus becoming clinically definite MS (CDMS) according to Poser's criteria; 46 (90.2%) patients converted to MS according to McDonald's criteria. Out of 51 patients, 28 (54.9%) had either double or single positivity for anti-myelin antibodies. Antibody status significantly predicted MS according to Poser's criteria (P=0.004), but did not according to the McDonald's criteria. When compared to antibody negative patients, the risk of developing a relapse was 8.9 (95% Cl: 2.7-29.8; P
| Original language | English |
|---|---|
| Pages (from-to) | 1086-1094 |
| Number of pages | 9 |
| Journal | Multiple Sclerosis Journal |
| Volume | 13 |
| Issue number | 9 |
| DOIs | |
| Publication status | Published - Nov 2007 |
Fingerprint
Keywords
- Clinically isolated syndrome
- MBP antibodies
- MOG antibodies
- MRI
- Multiple sclerosis
- Relapse
ASJC Scopus subject areas
- Clinical Neurology
Cite this
Anti-myelin antibodies predict the clinical outcome after a first episode suggestive of MS. / Tomassini, V.; De Giglio, L.; Reindl, M.; Russo, P.; Pestalozza, I.; Pantano, P.; Berger, T.; Pozzilli, Carlo.
In: Multiple Sclerosis Journal, Vol. 13, No. 9, 11.2007, p. 1086-1094.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Anti-myelin antibodies predict the clinical outcome after a first episode suggestive of MS
AU - Tomassini, V.
AU - De Giglio, L.
AU - Reindl, M.
AU - Russo, P.
AU - Pestalozza, I.
AU - Pantano, P.
AU - Berger, T.
AU - Pozzilli, Carlo
PY - 2007/11
Y1 - 2007/11
N2 - The aim of this study was to test the contribution of anti-myelin antibodies in predicting conversion from clinically isolated syndrome (CIS) to multiple sclerosis (MS) when considering either Poser's or McDonald's diagnostic criteria. Fifty-one patients with CIS and abnormal brain MRI were imaged monthly for six months and then at 12, 18, 24, 36 months. At baseline serum samples testing antibodies against myelin oligodendrocyte glycoprotein (anti-MOG) and myelin basic protein (anti-MBP) were collected. During the 36-month follow-up, 26 (51%) patients developed a relapse thus becoming clinically definite MS (CDMS) according to Poser's criteria; 46 (90.2%) patients converted to MS according to McDonald's criteria. Out of 51 patients, 28 (54.9%) had either double or single positivity for anti-myelin antibodies. Antibody status significantly predicted MS according to Poser's criteria (P=0.004), but did not according to the McDonald's criteria. When compared to antibody negative patients, the risk of developing a relapse was 8.9 (95% Cl: 2.7-29.8; P
AB - The aim of this study was to test the contribution of anti-myelin antibodies in predicting conversion from clinically isolated syndrome (CIS) to multiple sclerosis (MS) when considering either Poser's or McDonald's diagnostic criteria. Fifty-one patients with CIS and abnormal brain MRI were imaged monthly for six months and then at 12, 18, 24, 36 months. At baseline serum samples testing antibodies against myelin oligodendrocyte glycoprotein (anti-MOG) and myelin basic protein (anti-MBP) were collected. During the 36-month follow-up, 26 (51%) patients developed a relapse thus becoming clinically definite MS (CDMS) according to Poser's criteria; 46 (90.2%) patients converted to MS according to McDonald's criteria. Out of 51 patients, 28 (54.9%) had either double or single positivity for anti-myelin antibodies. Antibody status significantly predicted MS according to Poser's criteria (P=0.004), but did not according to the McDonald's criteria. When compared to antibody negative patients, the risk of developing a relapse was 8.9 (95% Cl: 2.7-29.8; P
KW - Clinically isolated syndrome
KW - MBP antibodies
KW - MOG antibodies
KW - MRI
KW - Multiple sclerosis
KW - Relapse
UR - http://www.scopus.com/inward/record.url?scp=39549088973&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=39549088973&partnerID=8YFLogxK
U2 - 10.1177/1352458507077622
DO - 10.1177/1352458507077622
M3 - Article
C2 - 17468447
AN - SCOPUS:39549088973
VL - 13
SP - 1086
EP - 1094
JO - Multiple Sclerosis
JF - Multiple Sclerosis
SN - 1352-4585
IS - 9
ER -